Monday , December 11 2017

dave

For over a year now we have had one of the premier hypertensive care physicians sharing his opinions and information on the treatment of hypertension. This week, Dr. George Bakris starts a new video series on hypertensive guidelines and how best to use them for patients. These choices become more important in light of the information we have learned from the recently published SPRINT Trial.

Many of you may not know that one of the drugs used in the SPRINT trial was a combination of azilsartan medoxomil and chlorthalidone, and that in 2012 Dr. Bakris did a study that was published in the American Journal of Medicine showing the value of chlorthalidone over HCTZ in blood pressure regulation in that combination. If chlorthalidone strikes you as an older medication and less likely to be used, you might find it interesting that Hygroton (chlorthalidone) came to market in 1960 and Hydrodiuril (hydrochlorothiazide) was approved in 1959. If you want to learn more about what Dr. Bakris found out about chlorthalidone, you may want to check out this item.

Your partner in diabetes care,
Dave Joffe
Editor-in-chief